The present study was undertaken to test whether the novel CB2 agonist GW842166x has neuroprotective effects against dopamine neuron loss and its associated motor deficits in the neurotoxic 6-hydroxydopamine (6-OHDA)-induced mouse model of PD, which has been extensively used to study motor function deficits within subjects by assessing rotational behavior [25,26]. The gene discussed is CNR2; the disease is Parkinson disease.